Purity
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit IL-22-induced IL-10 secretion by COLO 205 human colorectal adenocarcinoma cells. The ED 50 for this effect is 1-4 μg/mL in the presence of 0.5 ng/mL of Recombinant Mouse IL-22 (Catalog # ).
Source
Mouse myeloma cell line, NS0-derived
Mouse IL-22BP
(Thr19-Pro230)
Accession # Q08AV1IEGRMDP Mouse IgG2A
(Glu98-Lys330)N-terminus C-terminus Accession #
N-terminal Sequence
AnalysisThr19
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
51.8 kDa (monomer)
SDS-PAGE
60-70 kDa, reducing conditions
2376-BP |
| |
Formulation Lyophilized from a 0.2 μm filtered solution in PBS. | ||
Reconstitution Reconstitute at 250 μg/mL in sterile PBS. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: IL-22BP
Interleukin 22 binding protein (IL-22BP), also known as CRF2-10, CRF2-X, and IL-22 RA2, is a 35-45 kDa secreted glycoprotein in the type II cytokine receptor family (CRF). IL-22 signals through a receptor complex consisting of IL-22 R and IL-10 R beta. IL-10 R beta is also a component of the receptor complexes for IL-10, IL-26, IL-28, and IL-29 (1, 2). IL-22BP blocks the interaction of IL-22 with IL-22 R, preventing IL-22 induced production of reactive oxygen species, IL-6, IL-10, and TNF-a (3-8). In vivo, it regulates the proinflammatory effects of IL-22 ( e.g. neutrophil infiltration) but not of IL-10 (7). Mouse IL-22BP can neutralize the bioactivity of both mouse and human IL-22 (6). IL-22BP is produced by dendritic cells (DE), epithelial cells, activated B cells, and activated monocytes (3, 6, 9, 10). It is constitutively expressed by DC but is down-regulated during local inflammation and in response to tissue damage (11-13). IL-22BP is critical for limiting IL-22 induced epithelial cell proliferation during wound healing, and its deficiency can enable uncontrolled proliferation and enhance tumor development (12). Mature mouse IL-22BP consists of two tandem Fibronectin type-III domains and shares 85% and 68% amino acid sequence identity with rat IL-22BP and the short isoform of human IL-22BP, respectively (6, 14).
References:
Lim, C. and R. Savan (2014) Cytokine Growth Factor Rev. 25:257.
Mizoguchi, A. (2012) Inflamm. Bowel Dis. 18:1777.
Xu, W. et al. (2001) Proc. Natl. Acad. Sci. USA 98:9511.
Kotenko, S.V. et al. (2001) J. Immunol. 166:7096.
Li, J. et al. (2004) Int. Immunopharmacol. 4:693.
Wei, C.-C. et al. (2003) Genes Immun. 4:204.
Weber, G.F. et al. (2007) Infect. Immun. 75:1690.
Whittington, H.A. et al. (2004) Am. J. Respir. Cell Mol. Biol. 31:220.
Lecart, S. et al. (2002) Int. Immunol. 14:1351.
Nagalakshmi, M.L. et al. (2004) Int. Immunopharmacol. 4:577.
Wolk, K. et al. (2007) J. Immunol. 178:5973.
Huber, S. et al. (2012) Nature 491:259.
Martin, J.C.J. et al. (2014) Mucosal Immunol. 7:101.
Weiss, B. et al. (2004) Genes Immun. 5:330.
Long Name:
Interleukin 22 Binding Protein
Entrez Gene IDs:
116379 (Human); 237310 (Mouse)
Alternate Names:
class II cytokine receptor; CRF2-10; CRF2-S1IL22BP; CRF2-X; Cytokine receptor class-II member 10; Cytokine receptor family 2 member 10; Cytokine receptor family type 2, soluble 1; IL-22 RA2; IL-22 receptor subunit alpha-2; IL22BP; IL-22BP; IL-22BPCRF2X; IL22RA2; IL-22RA2; IL-22R-alpha-2; interleukin 22 receptor, alpha 2; interleukin 22-binding protein; interleukin-22 receptor subunit alpha-2; Interleukin-22-binding protein; MGC150509; MGC150510; zcytoR16
